» Articles » PMID: 38212484

Body Size and Risk of Multiple Myeloma in the Black Women's Health Study

Overview
Journal Br J Cancer
Specialty Oncology
Date 2024 Jan 11
PMID 38212484
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Obesity is an established risk factor for multiple myeloma (MM). Relatively few prior studies, however, have evaluated associations in Black populations.

Methods: Among 55,276 participants in the Black Women's Health Study, a prospective U.S. cohort established in 1995, we confirmed 292 incident diagnoses of MM over 26 years of follow-up. Multivariable Cox proportional hazard models, adjusted for age and putative MM risk factors, were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations of usual body mass index (BMI), BMI at age 18, height, and waist-to-hip ratio with MM.

Results: Compared to women with a usual adult BMI < 25 kg/m, the HR associated with a usual adult BMI ≥ 35 kg/m was 1.38 (95% CI: 0.96, 1.98). For early adult BMI, the HR comparing women with BMI ≥ 25 vs. <25 kg/m was 1.57 (95% CI: 1.08, 2.28). Women who were heavy in both early and later life had the highest risk compared to those who were lean at both time points (HR: 1.60; 95% CI: 1.02, 2.52). Height was also associated with the risk of MM; the HR per 10 cm was 1.21 (95% CI: 1.02, 1.43).

Conclusions: These results indicate that high early adult BMI is associated with a 57% increased risk of MM in Black women and potentially highlight the importance of weight control as a preventive measure.

References
1.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K . Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016; 375(8):794-8. PMC: 6754861. DOI: 10.1056/NEJMsr1606602. View

2.
Liu B, Du Y, Wu Y, Snetselaar L, Wallace R, Bao W . Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. BMJ. 2021; 372:n365. PMC: 7961695. DOI: 10.1136/bmj.n365. View

3.
Sprynski A, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi J . Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia. 2010; 24(11):1940-50. PMC: 3141222. DOI: 10.1038/leu.2010.192. View

4.
Liu R, Gao D, Lv Y, Zhai M, He A . Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies. BMC Endocr Disord. 2022; 22(1):29. PMC: 8787905. DOI: 10.1186/s12902-022-00939-2. View

5.
Bieghs L, Johnsen H, Maes K, Menu E, Van Valckenborgh E, Overgaard M . The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget. 2016; 7(30):48732-48752. PMC: 5217049. DOI: 10.18632/oncotarget.8982. View